Literature DB >> 20350989

Progression of preclinical diastolic dysfunction to the development of symptoms.

Daniel D Correa de Sa1, David O Hodge, Joshua P Slusser, Magaret M Redfield, Robert D Simari, John C Burnett, Horng H Chen.   

Abstract

BACKGROUND: Preclinical diastolic dysfunction (PDD) has been defined as subjects with normal systolic function, diastolic dysfunction but no symptoms of heart failure (HF). The clinical phenotype and natural history of the syndrome remains poorly defined. This study's objective was to determine the clinical phenotype and progression to HF in a group of patients with normal systolic function and moderate or severe diastolic dysfunction as determinate by Doppler criteria without any clinical diagnosis of HF according to the Framingham criteria or any symptoms of HF, specifically dyspnoea, oedema or fatigue at the time of echocardiography.
METHODS: The authors used resources of the Mayo Clinic echocardiography database to consecutively select among patients who had an echocardiogram in 2005, a cohort with moderate or severe diastolic dysfunction by Doppler criteria and EF >or=50%. Patients could not have a diagnosis of HF, or any HF symptoms-specifically dyspnoea, oedema or fatigue-at the time of echocardiography; nor grade 3 or greater valvular dysfunction (except tricuspid valve). A total of 82 patients had their medical chart reviewed. Primary endpoint was the time to the development of (1) HF according to the Framingham criteria or (2) any symptoms of dyspnoea, oedema or fatigue.
RESULTS: The mean age of the cohort of PDD subjects was 69+/-10 years with a female (67%) preponderance. Presence of hypertension was 76%, coronary artery disease was 29%, paroxysmal atrial fibrillation was 26%, estimated creatinine clearance <60 ml/min was 51%. The 2-year cumulative probability of development of HF according to the Framingham criteria was 1.9%; however, the 2-year cumulative probability of development of any symptoms was 31.1%. The 2-year cumulative probability for cardiac hospitalisation was 21.2%. Peripheral vascular disease and hypertension were independently associated with increased likelihood for the development of symptoms.
CONCLUSION: The study demonstrates that hypertension, hyperlipidaemia, CAD and renal dysfunction are prevalent in patients with PDD. More importantly, although the progression to the development of clinical HF over 2 years was low, there was a moderate degree of progression to development of symptoms and cardiac hospitalisations over 2 years. Based on the finding that only PVD and hypertension were independently associated with the progression to the development of symptoms in subject with PDD, the authors speculate that ventricular-arterial interaction may be important to the progression of diastolic dysfunction to the development of symptoms.

Entities:  

Mesh:

Year:  2010        PMID: 20350989      PMCID: PMC2977526          DOI: 10.1136/hrt.2009.177980

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  19 in total

Review 1.  Recommendations for chamber quantification.

Authors:  Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack Shanewise; Scott Solomon; Kirk T Spencer; Martin St John Sutton; William Stewart
Journal:  Eur J Echocardiogr       Date:  2006-02-02

2.  Diastolic heart failure in the community: clinical profile, natural history, therapy, and impact of proposed diagnostic criteria.

Authors:  Horng H Chen; John G Lainchbury; Michele Senni; Kent R Bailey; Margaret M Redfield
Journal:  J Card Fail       Date:  2002-10       Impact factor: 5.712

3.  Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota.

Authors:  Carolyn S P Lam; Véronique L Roger; Richard J Rodeheffer; Francesca Bursi; Barry A Borlaug; Steve R Ommen; David A Kass; Margaret M Redfield
Journal:  Circulation       Date:  2007-04-02       Impact factor: 29.690

Review 4.  Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography.

Authors:  Jae K Oh; Liv Hatle; A Jamil Tajik; William C Little
Journal:  J Am Coll Cardiol       Date:  2006-01-18       Impact factor: 24.094

5.  Systolic and diastolic heart failure in the community.

Authors:  Francesca Bursi; Susan A Weston; Margaret M Redfield; Steven J Jacobsen; Serguei Pakhomov; Vuyisile T Nkomo; Ryan A Meverden; Véronique L Roger
Journal:  JAMA       Date:  2006-11-08       Impact factor: 56.272

6.  Evolution and outcome of diastolic dysfunction.

Authors:  N Achong; S Wahi; T H Marwick
Journal:  Heart       Date:  2008-12-15       Impact factor: 5.994

7.  Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations.

Authors:  Miho Kawaguchi; Ilan Hay; Barry Fetics; David A Kass
Journal:  Circulation       Date:  2003-02-11       Impact factor: 29.690

8.  Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study.

Authors:  Carolyn S P Lam; Véronique L Roger; Richard J Rodeheffer; Barry A Borlaug; Felicity T Enders; Margaret M Redfield
Journal:  J Am Coll Cardiol       Date:  2009-03-31       Impact factor: 24.094

9.  Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic.

Authors:  Margaret M Redfield; Steven J Jacobsen; John C Burnett; Douglas W Mahoney; Kent R Bailey; Richard J Rodeheffer
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

10.  Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography.

Authors:  Teresa S M Tsang; Marion E Barnes; Bernard J Gersh; Yasuhiko Takemoto; A Gabriela Rosales; Kent R Bailey; James B Seward
Journal:  J Am Coll Cardiol       Date:  2003-10-01       Impact factor: 24.094

View more
  29 in total

1.  The natural history of preclinical diastolic dysfunction: a population-based study.

Authors:  Mark W Vogel; Joshua P Slusser; David O Hodge; Horng H Chen
Journal:  Circ Heart Fail       Date:  2012-01-25       Impact factor: 8.790

2.  Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community.

Authors:  Carolyn S P Lam; Asya Lyass; Elisabeth Kraigher-Krainer; Joseph M Massaro; Douglas S Lee; Jennifer E Ho; Daniel Levy; Margaret M Redfield; Burkert M Pieske; Emelia J Benjamin; Ramachandran S Vasan
Journal:  Circulation       Date:  2011-06-13       Impact factor: 29.690

3.  Left ventricular diastolic function as a possible predictor of severe carfilzomib-induced cardiovascular events.

Authors:  Yoshiaki Abe; Tetsuya Kobayashi; Kentaro Narita; Hiroki Kobayashi; Akihiro Kitadate; Daisuke Miura; Masami Takeuchi; Kosei Matsue
Journal:  Blood Adv       Date:  2019-06-11

Review 4.  Role of estrogen in diastolic dysfunction.

Authors:  Zhuo Zhao; Hao Wang; Jewell A Jessup; Sarah H Lindsey; Mark C Chappell; Leanne Groban
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-01-10       Impact factor: 4.733

5.  Activation of GPR30 inhibits cardiac fibroblast proliferation.

Authors:  Hao Wang; Zhuo Zhao; Marina Lin; Leanne Groban
Journal:  Mol Cell Biochem       Date:  2015-04-17       Impact factor: 3.396

6.  Correlation between Subclinical Heart Disease and Cardiovascular Risk Profiles in an Urban Emergency Department Population with Elevated Blood Pressures: A Pilot Study.

Authors:  Heather M Prendergast; Joseph Colla; Neal Patel; Marina Del Rios; Jared Marcucci; Ryan Scholz; Patience Ngwang; Katherine Cappitelli; Martha Daviglus; Samuel Dudley
Journal:  J Emerg Med       Date:  2015-03-20       Impact factor: 1.484

Review 7.  Current perspectives on systemic hypertension in heart failure with preserved ejection fraction.

Authors:  A Afşin Oktay; Sanjiv J Shah
Journal:  Curr Cardiol Rep       Date:  2014-12       Impact factor: 2.931

Review 8.  Cardiorenal syndrome: pathophysiology and potential targets for clinical management.

Authors:  Parta Hatamizadeh; Gregg C Fonarow; Matthew J Budoff; Sirous Darabian; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nat Rev Nephrol       Date:  2012-12-18       Impact factor: 28.314

9.  Left ventricular diastolic function and long-term outcomes in patients with normal exercise echocardiographic findings.

Authors:  S Michael Gharacholou; Christopher G Scott; Paul Y Takahashi; Vuyisile T Nkomo; Robert B McCully; Nowell M Fine; Patricia A Pellikka
Journal:  Am J Cardiol       Date:  2013-04-20       Impact factor: 2.778

Review 10.  Pre-clinical diastolic dysfunction.

Authors:  Siu-Hin Wan; Mark W Vogel; Horng H Chen
Journal:  J Am Coll Cardiol       Date:  2013-11-27       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.